<DOC>
	<DOCNO>NCT02087813</DOCNO>
	<brief_summary>Neuromyelitis Optica ( NMO ) rare , devastate demyelinate disease central nervous system ( CNS ) different cause treatment common demyelinate disease multiple sclerosis ( MS ) . Current NMO therapy nonspecific vary often suboptimal benefit . The investigator evaluate whether use alpha1-antitrypsin ( A1AT , FDA-approved medication patient congenital deficiency A1AT associate emphysema ) benefit acute attack NMO , improve patient disability quality life .</brief_summary>
	<brief_title>Pilot Study alpha1-antitrypsin Treat Neuromyelitis Optica Relapses</brief_title>
	<detailed_description />
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Provide write informed consent . Age ≥18 ≤ 75 year . Diagnosis NMO NMO spectrum disorder ( NMOSD ) . The diagnosis NMO conform 2006 Wingerchuk criteria.1 , 2 The diagnosis NMOSD include patient relapse optic neuritis aquaporin4 antibody ( AQP4 ) seropositivity patient relapse longitudinally extensive transverse myelitis AQP4 seropositivity.25 NMO NMOSD collectively refer NMO . AQP4antibody positivity . Present acute NMO attack ( see definition ) . Patients must history clinically significant infusion reaction administration biologic agent . If chronic treatment NMO , treatment initiate least 3 month early medication dose stable . Additional restriction place change concomitant symptomatic medication . A female subject childbearing potential must negative serum pregnancy test screen visit agree use medically reliable method contraception ( e.g. , barrier either spermicide hormonal contraception ) study completion . Agree answer question Columbia Suicide Severity Rating Scale specify visit . A woman pregnant , breastfeeding , plan pregnancy . If patient enrol experimental trial experimental therapy . If patient know IgA deficiency IgAantibodies . Any medical condition clinically significant laboratory abnormality Investigator 's judgment may affect patient 's ability safely complete study . Acute attack : The occurrence new worsen neurological symptom consistent optic neuritis , transverse myelitis , brain lesion develop acutely ( i.e. , patient must present within 7 day symptom onset ) . The symptom must persist least 48 hour , attributable confound clinical factor ( e.g. , fever , infection , injury , adverse reaction concomitant medication ) . The symptom must accompany sensory , motor visual acuity objective deficit , must verify examine physician . A single episode paroxysmal symptom ( e.g. , tonic spasm ) relapse ; however , new onset multiple occurrence paroxysmal symptom least 48 hour relapse accompany new , corresponding objective deficit . Sensory symptom change clinical examination , fatigue , mood change , bladder bowel urgency incontinence sufficient establish relapse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>neuromyelitis optica</keyword>
	<keyword>optic neuritis</keyword>
	<keyword>longitudinally extensive transverse myelitis</keyword>
</DOC>